Other risk factors include reduced muscle mass and lower levels of physical activity.
A recent study resulted in a new definition of less-than-optimal response to erythropoiesis-stimulating agents.
A hemoglobin level of 10.5 g/dL offers the optimal balance of cost and quality adjusted life years, researchers conclude.
The odds of developing anemia were 2-fold greater among patients with than without diabetes mellitus.
Anemia was associated with impaired activity levels at CKD stages 3, 4, and dialysis.
IV administration of vitamin B6 did not improve anemia or abnormal bone metabolism over 6 months.
Average weekly doses greater than 70 µg/week was associated with a 77% increased risk of cancer compared with no ESA exposure.
A high erythropoietin resistance index was associated with triple the risk for death from any cause.
Patients provided small doses of intravenous iron per treatment achieved higher hemoglobin levels than patients receiving weekly iron.
In a small study, 82% of patients had iron overload prior to hemodialysis initiation.
Less than half of anemic patients were prescribed ESAs or iron in the US and France, and a high percentage overall did not have iron indices measured.
Investigators find that the normalized mean ESA dose decreases as patients' elevation of residence increases.
Researchers confirmed higher dose conversion ratios in Taiwanese patients with stable hemoglobin.
New findings implicate transferrin saturation and nutritional status assessed by albumin.
After 54 weeks of treatment with testosterone undecanoate, anemia prevalence decreased from 29.6% to 10%.
A summary of Dr. Jeffrey S. Berns' presentation that will be given at the National Kidney Foundation's 2016 Spring Clinical Meetings in Boston, MA.
Trend is independent of intravenous iron use and exposure to erythropoiesis-stimulating agents.
No new adverse events observed in patients with underlying cardiovascular risk factors who switched to continuous erythropoietin receptor activator.
Greater hyporesponsiveness to erythropoiesis-stimulating agents was associated with increased PLR ratios.
Observed rates of all-cause and cardiovascular mortality and myocardial infarction were consistent with expected rates, study shows.
Researchers observe significantly higher levels of albumin and hemoglobin and better calcium and phosphate metabolism.
Based on effect of erythropoietin-stimulating agents for higher hemoglobin targets.
In a phase 2 trial, roxadustat maintained hemoglobin levels over 19 weeks as well as epoetin alfa.
In a case-control study, the treatment did not adversely affect mortality or recovery from AKI.
Study shows benefit of initiating epoetin beta therapy at hemoglobin levels not less than 10 g/dL in non-dialysis CKD patients.
Treatment corrects anemia and improves quality of life, according to a systemic review.
Six-months of supplementation has no impact on epoetin utilization in HD patients with low 25(OH)D.
In a study, investigators observed that levels were higher in those with stage 3a than stage 3b chronic kidney disease.
The estimated potential staff time savings totaled 23 hours for an average facility with 70 patients, researchers found.
Rates of death and important non-fatal outcomes between ferumoxytol and iron sucrose or sodium ferric gluconate do not differ significantly.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)